Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Prophylactic Treatment with New Recombinant Factor IX Innonafactor (Russia) in Adolescent and Adult Patients with Hemophilia B

Ekaterina Shiller, Victor Petrov, MD PhD, Pavel Svirin, MD, Vladimir Vdovin, MD, Igor Koltunov, MD PhD, Artyom Bullih, Michael A Maschan, Dmitry Kudlay, MD PhD Prof., Ekaterina Klykova, MD PhD

Blood (2017) 130 (Supplement 1): 4895.

https://doi.org/10.1182/blood.V130.Suppl_1.4895.4895

Published: 2017

Journal Articles

Long-Term Prophylaxis with Activated Recombinant FVII in Children with Hemophilia a and Inhibitor, Receiving Treatment with ITI Protocol

Ekaterina Shiller, MD, Victor Petrov, MD PhD, Pavel Svirin, MD, Vladimir Vdovin, MD, Igor Koltunov, MD PhD, Artem Bullikh, MD, Eugene Nikitin, MD PhD, Dmitry Kudlay, MD PhD Prof., Ekaterina Klykova, MD PhD

Blood (2016) 128 (22): 4980.

https://doi.org/10.1182/blood.V128.22.4980.4980

Published: 2016

Journal Articles

Safety and Efficiency of New Nonacog Alfa Drug in the Treatment of Bleeding Episodes in Patients with Severe and Moderate Hemophilia B

Igor Davydkin, Prof., Tatiana Andreeva, MD PhD, Vladimir Yu. Zorenko, MD PhD Prof., Valeria Konstantinova, MD PhD, Olga Zalepukhina, MD, Nina Klimova, MD, Georgy Mishin, MD, Igor Kurtov, MD PhD, Maria Shamina, MD PhD, Elena Fatenkova, MD, Olga Gusyakova, MD PhD, Alexandr Shuster, Academician, PhD, Dmitry Kudlay, MD PhD Prof., Sergey Lukyanov, MD PhD, Anton Borozinets, MD PhD, Eugene Nikitin, MD PhD, Ekaterina Klykova, MD PhD

Blood (2015) 126 (23): 4690.

https://doi.org/10.1182/blood.V126.23.4690.4690

Published: 2015

Journal Articles

The Pharmacokinetic Properties, Safety and Tolerability of a New Nonacog Alfa (Innonafactor) in Patients with Hemophilia B

Vladimir Yu. Zorenko, MD PhD Prof., Georgy Mishin, MD, Tatiana Severova, MD, Alexandr Shuster, Academician, PhD, Dmitry Kudlay, MD PhD Prof., Sergey Lukyanov, MD PhD, Anton Borozinets, MD PhD, Eugene Nikitin, MD PhD, Ekaterina Klykova, MD PhD

Blood (2015) 126 (23): 4691.

https://doi.org/10.1182/blood.V126.23.4691.4691

Published: 2015

Journal Articles

Safety and Efficacy of New Moroctocog Alfa Drug (Octofactor) in Prophylactic Treatment in Adolescent Patients with Severe and Moderate Hemophilia a

Ekaterina Shiller, MD, Vladimir Vdovin, MD, Victor Petrov, MD PhD, Pavel Svirin, MD, Tatiana Andreeva, MD PhD, Inna Lavrichenko, MD, Artem Bullikh, MD, Igor Koltunov, MD PhD, Igor Davydkin, Prof., Igor Kurtov, MD PhD, Alexandr Shuster, Academician, PhD, Dmitry Kudlay, MD PhD Prof., Sergey Lukyanov, MD PhD, Anton Borozinets, MD PhD, Eugene Nikitin, MD PhD, Ekaterina Klykova, MD PhD

Blood (2015) 126 (23): 4703.

https://doi.org/10.1182/blood.V126.23.4703.4703

Published: 2015

Journal Articles

Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B

Tatiana Andreeva, MD PhD, Vladimir Yu. Zorenko, MD PhD Prof., Igor Davydkin, Prof., Valeria Konstantinova, MD PhD, Olga Zalepukhina, MD, Nina Klimova, MD, Georgy Mishin, MD, Igor Kurtov, MD PhD, Maria Shamina, MD PhD, Elena Fatenkova, MD, Olga Gusyakova, MD PhD, Alexandr Shuster, Academician, PhD, Dmitry Kudlay, MD PhD Prof., Sergey Lukyanov, MD PhD, Anton Borozinets, MD PhD, Eugene Nikitin, MD PhD, Ekaterina Klykova, MD PhD

Blood (2015) 126 (23): 3532.

https://doi.org/10.1182/blood.V126.23.3532.3532

Published: 2015

NARROW

Prophylactic Treatment with New Recombinant Factor IX Innonafactor (Russia) in Adolescent and Adult Patients with Hemophilia B

Long-Term Prophylaxis with Activated Recombinant FVII in Children with Hemophilia a and Inhibitor, Receiving Treatment with ITI Protocol

Safety and Efficiency of New Nonacog Alfa Drug in the Treatment of Bleeding Episodes in Patients with Severe and Moderate Hemophilia B

The Pharmacokinetic Properties, Safety and Tolerability of a New Nonacog Alfa (Innonafactor) in Patients with Hemophilia B

Safety and Efficacy of New Moroctocog Alfa Drug (Octofactor) in Prophylactic Treatment in Adolescent Patients with Severe and Moderate Hemophilia a

Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B

Email alerts

ASH Publications

American Society of Hematology

Prophylactic Treatment with New Recombinant Factor IX Innonafactor (Russia) in Adolescent and Adult Patients with Hemophilia B

Long-Term Prophylaxis with Activated Recombinant FVII in Children with Hemophilia a and Inhibitor, Receiving Treatment with ITI Protocol

Safety and Efficiency of New Nonacog Alfa Drug in the Treatment of Bleeding Episodes in Patients with Severe and Moderate Hemophilia B

The Pharmacokinetic Properties, Safety and Tolerability of a New Nonacog Alfa (Innonafactor) in Patients with Hemophilia B

Safety and Efficacy of New Moroctocog Alfa Drug (Octofactor) in Prophylactic Treatment in Adolescent Patients with Severe and Moderate Hemophilia a

Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only